To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.

Front Cardiovasc Med · 2025 · PMC12325361 · PMID 40771762

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The pooled analysis demonstrated an elevated risk of composite renal adverse events in patients treated with MRAs [RR: 1.202 (95% CI: 0.830, 1.743), p = 0.330; I 2 = 52.9%], though the result did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.